Add to ORKGResistance to imatinib is a significant clinical issue, and the underlying mechanism of this resistance is multifactorial. The efficacy of imatinib in chronic myeloid leukemia (CML) in achieving a high remission rate and improving prognosis has seriously been challenged by the development of mutants of BCR-ABL gene, which resist the action of imatinib, which is a tyrosine kinase inhibitor. We present here a case of a 35-year-old male, a known case of CML on imatinib therapy, the patient eventually landed in blast crisis and succumbed to the disease and secondary infections
Development of resistance to imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients is ...
none20noPURPOSE: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associat...
Purpose Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with c...
The BCR-ABL tyrosine kinase inhibitor Imatinib is highly effective for chronic myeloid leukemia (CML...
AbstractThe fusion tyrosine kinase Bcr-Abl plays a fundamental role in the pathogenesis of chronic m...
Selective inhibition of the BCR-ABL tyrosine kinase by imatinib (STI571, Glivec/Gleevec) is a promis...
Background: The vast majority of chronic myeloid leukemia (CML) patients express the BCR-ABL transcr...
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder caused by BCR-ABL1 igureusion encod...
Introduction - The management and long-term outcome of patients affected by chronic myeloid leukemia...
Purpose: BCR-ABL kinase domain (KD) mutations account for 50-90% of the imatinib resistance observed...
Chronic myeloid leukemia (CML) is a malignant hematopoietic stem cell disease resulting in the fusio...
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all st...
The majority of patients with chronic phase chronic myeloid leukaemia (CP-CML) treated with imatinib...
Chronic myeloid leukemia (CML) is a disorder of blood stem cells in bone marrow, which leads to a ra...
Recently, IMATINffi MESYLATE (IM), a selective Tyrosine Kinase inhibitor, is widely used as a frontl...
Development of resistance to imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients is ...
none20noPURPOSE: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associat...
Purpose Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with c...
The BCR-ABL tyrosine kinase inhibitor Imatinib is highly effective for chronic myeloid leukemia (CML...
AbstractThe fusion tyrosine kinase Bcr-Abl plays a fundamental role in the pathogenesis of chronic m...
Selective inhibition of the BCR-ABL tyrosine kinase by imatinib (STI571, Glivec/Gleevec) is a promis...
Background: The vast majority of chronic myeloid leukemia (CML) patients express the BCR-ABL transcr...
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder caused by BCR-ABL1 igureusion encod...
Introduction - The management and long-term outcome of patients affected by chronic myeloid leukemia...
Purpose: BCR-ABL kinase domain (KD) mutations account for 50-90% of the imatinib resistance observed...
Chronic myeloid leukemia (CML) is a malignant hematopoietic stem cell disease resulting in the fusio...
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all st...
The majority of patients with chronic phase chronic myeloid leukaemia (CP-CML) treated with imatinib...
Chronic myeloid leukemia (CML) is a disorder of blood stem cells in bone marrow, which leads to a ra...
Recently, IMATINffi MESYLATE (IM), a selective Tyrosine Kinase inhibitor, is widely used as a frontl...
Development of resistance to imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients is ...
none20noPURPOSE: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associat...
Purpose Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with c...